Pharmafile.com’s weekly COVID-19 news round-up
pharmafile | March 31, 2021 | News story | Research and Development | COVID-19, covid 19 news, covid-19 news, covid-19 roundup
The past week has seen plenty of positive COVID-19 news; Starpharma are to start selling their COVID-fighting nose spray in the UK, GSK & Vir’s treatment for the virus has shown an efficacy of 85% in a Phase III trial, and Johnson & Johnson are set to ship as many as 400 million vaccines to African Union countries.
1. J & J to ship up to 400 million vaccines to Africa – Published 30/03/2021
Johnson & Johnson has reached an agreement to ship as many as 400 million doses of their COVID-19 vaccine to African Union (AU) member states.
2. 500,000 Moderna COVID-19 vaccines to arrive in UK next month – Published 29/03/21
More than 500,000 doses of Moderna’s COVID-19 vaccine are set to arrive in the UK next month, ministers have confirmed.
3. GSK & Vir’s COVID-19 treatment shows 85% efficacy in Phase III trial – Published 29/03/21
GSK and Vir Biotechnology have submitted an Emergency Use Authorization request to the FDA for their VIR-7831 therapy for the treatment of COVID-19.
4. Starpharma to sell COVID-fighting nose spray in UK – Published – 25/03/21
Australian biotech company, Starpharma, has announced a deal with LloydsPharmacy to sell its COVID-fighting antiviral nasal spray, Viraleze, in the UK.
5. AstraZeneca vaccine found to be 3% less effective after further trial analysis – Published 25/03/21
AstraZeneca have revised their findings from the US study AZD1222 of their COVID-19 vaccine, announcing a 76% efficacy against symptoms of the virus, as opposed to the 79% efficacy reported on Monday.
Jack Goddard
Related Content
Gilead’s Veklury recommended by NICE for COVID-19 treatment
Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has …
NICE expands access to Paxlovid for 1.4 million people at risk of severe COVID-19
The National Institute for Health and Care Excellence (NICE) has announced that it has expanded …
Moderna shares data from phase 1/2 trial for combination flu and COVID-19 vaccine
Moderna has announced positive interim results from the phase 1/2 trial of mRNA-1083, its investigational …